Profitability Metrics

Gross Margin
43.78%
Operating Margin
43.38%
Net Margin
41.90%

Efficiency Metrics

Revenue per Expense Ratio
1.77
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
90.97%
Income Tax Rate
3.11%
EPS
2.8000000000

Balance Sheet Analysis

Current Ratio
0.70
Cash Ratio
0.43
Working Capital
$-132.91M
Debt to Equity
87.41
Debt to Assets
48.39%
Equity Ratio
0.55%

Cash Flow Analysis

Operating Cash Flow Ratio
49.90%
Free Cash Flow Ratio
29.54%
CapEx to Revenue
20.36%
Dividends Paid
$74.94M
Stock Buybacks
$3.97M
Total Shareholder Returns
$78.91M
Cash Position Change
-30.66%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 159.44%

Detailed Growth Metrics

Core Performance

Revenue
16.38%
Net Income
35.90%
EPS
25.56%
Operating Income
77.77%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-11.34%
Operating Cash Flow
31.03%
Free Cash Flow
27.22%

Balance Sheet Health

Assets
-1.86%
Debt
-12.21%
Book Value per Share
0.48%
Inventory
-112.17%

Shareholder Returns

Dividends per Share
159.44%
Shares Outstanding
12.81%

Long Term Trends

3Y Revenue/Share
0.89%
5Y Revenue/Share
13.43%
3Y Dividend/Share
-41.10%
5Y Dividend/Share
-15.08%